The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

In this Science segment, we examine the European Medicines Agency's recent decision to recommend granting marketing ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

A new Alzheimer’s test collects just a few drops of blood from a finger prick, which can be mailed to a lab for analysis.

European regulators initially said in July that the drug's benefits did not outweigh its risks. View on euronews ...

Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and ...

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...

It is estimated that less than one in ten people with dementia are eligible for treatment with Lecanemab or Leqembi, the ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...

The association said new treatments have become available that slow the progression of Alzheimer’s for those in the early ...